Updates T-DXd (gastric) & SC Dara (AL Amyloidosis)
Jan 21, 2021•18 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Discussing recent FDA approvals for expanded indications for trastuzumab-deruxtecan for gastric cancer (based on DESTINY-Gastric01) and SC daratumumab for AL amyloidosis.
DESTINY-Gastric01: https://www.nejm.org/doi/full/10.1056/NEJMoa2004413
For the best experience, listen in Metacast app for iOS or Android